Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact Contact Barchart
Market:

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability Business Wire - Tue Jan 10, 3:05PM CST

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 48.04 (-0.29%)
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs Business Wire - Tue Jan 10, 3:05PM CST

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 48.04 (-0.29%)
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio Zacks - Fri Jan 6, 9:11AM CST

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

MMSI : 69.94 (+0.60%)
AMN : 96.32 (-2.65%)
MLAB : 193.27 (+0.56%)
GKOS : 48.04 (-0.29%)
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference Business Wire - Wed Dec 28, 2022

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 48.04 (-0.29%)
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio Zacks - Wed Dec 28, 2022

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.

MMSI : 69.94 (+0.60%)
EXAS : 67.48 (+3.75%)
GKOS : 48.04 (-0.29%)
SWAV : 187.83 (-3.50%)
Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue? Zacks - Fri Dec 2, 2022

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GKOS : 48.04 (-0.29%)
TFX : 243.86 (+1.18%)
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio Zacks - Wed Nov 23, 2022

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

MCK : 379.20 (-1.28%)
AMN : 96.32 (-2.65%)
GKOS : 48.04 (-0.29%)
LNTH : 56.20 (+0.64%)
Here's Why Glaukos (GKOS) Could be Great Choice for a Bottom Fisher Zacks - Mon Nov 7, 2022

After losing some value lately, a hammer chart pattern has been formed for Glaukos (GKOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions,...

GKOS : 48.04 (-0.29%)
Glaukos Announces Participation in the Stephens Annual Investment Conference Business Wire - Mon Nov 7, 2022

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced...

GKOS : 48.04 (-0.29%)
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View Zacks - Thu Nov 3, 2022

Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.

MMSI : 69.94 (+0.60%)
GKOS : 48.04 (-0.29%)
MEDP : 223.68 (-1.78%)
ELV : 492.53 (-1.92%)

Barchart Exclusives

Is Corn Ready for a Seasonal February Rally? Barchart - Fri Jan 27, 4:32PM CST
After correcting a portion of the recent rally off the seasonal lows, corn appears to be ready to resume its post-harvest rally, as February has historically seen the uptrend continue into the first week of March. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot